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doi:10.1016/j.kjms.2011.05.003Abstract Chronic arsenic toxicity (arsenicosis) as a result of drinking arsenic-contaminated
groundwater is a major environmental health hazard throughout the world, including India.
A lot of research on health effects, including genotoxic effect of chronic arsenic toxicity in hu-
mans, have been carried out in West Bengal during the last 2 decades. A review of literature
including information available from West Bengal has been made to characterize the problem.
Scientific journals, monographs, and proceedings of conferences with regard to human health
effects, including genotoxicity, of chronic arsenic toxicity have been reviewed. Pigmentation
and keratosis are the specific skin diseases characteristic of chronic arsenic toxicity. However,
in West Bengal, it was found to produce various systemic manifestations, such as chronic lung
disease, characterized by chronic bronchitis, chronic obstructive and/or restrictive pulmonary
disease, and bronchiectasis; liver diseases, such as non cirrhotic portal fibrosis; polyneuropa-
thy; peripheral vascular disease; hypertension; nonpitting edema of feet/hands; conjunctival
congestion; weakness; and anemia. High concentrations of arsenic, greater than or equal to
200 mg/L, during pregnancy were found to be associated with a sixfold increased risk for still-
birth. Cancers of skin, lung, and urinary bladder are the important cancers associated with this
toxicity. Of the various genotoxic effects of arsenic in humans, chromosomal aberration and
increased frequency of micronuclei in different cell types have been found to be significant.
Various probable mechanisms have been incriminated to cause DNA damage because of chronic
arsenic toxicity. The results of the study in West Bengal suggest that deficiency in DNA repair
capacity, perturbation of methylation of promoter region of p53 and p16 genes, and genomic
methylation alteration may be involved in arsenic-induced disease manifestation in humans.
P53 polymorphism has been found to be associated with increased occurrence of arsenic-
induced keratosis. Of the various genes involved in the regulation of arsenic metabolism,
single-nucleotide polymorphisms of purine nucleoside phosphorylase, in one study, showed
increased occurrence of arsenicosis.
Copyright ª 2011, Elsevier Taiwan LLC. All rights reserved.rch Foundation, 37/C, Block B, New Alipore, Kolkata 700 053, India.
ahoo.com (D.N. Guha Mazumder).
vier Taiwan LLC. All rights reserved.
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Reports of arsenic contamination in water are available
from more than 30 countries in the world. However, the
major regions affected are in the river basins of the Ganga,Figure 1. Map oBrahmaputra, and Meghna in India and Bangladesh and
those in China. It is suspected that about 6 million people
in West Bengal (Fig. 1), India, are exposed to arsenic-
contaminated groundwater [1]. The occurrence of a large
number of cases of arsenic-induced skin lesions wasf West Bengal.
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then, incidences of chronic arsenic toxicity have been
reported in most of the states adjoining the upper, middle,
and lower Ganga and Brahmaputra plains. Arsenic
contamination has been found in the states of Bihar, Uttar
Pradesh, Jharkhand, Assam, Chhattisgarh, and Andhra
Pradesh [3,4]. As a large amount of data have been
generated from research on clinical health effect and
genotoxicity in man as a result of drinking arsenic-
contaminated groundwater in West Bengal, India, this
article has focused attention to present data on results of
research in these areas in two sections and has incorpo-
rated a review of relevant literature from studies in other
countries. Because of space constraints, the literature
survey could not be exhaustive.
Human health effect (arsenicosis)
The term arsenicosis to designate human health effect of
chronic arsenic toxicity was first coined by our group [5]
and later used by the World Health Organization [6] to
imply a chronic disease caused by prolonged exposure of
arsenic in humans. Previously, the condition was described
as arseniasis, arsenism, arsenicism, and others. Most of the
reports of chronic arsenic exposure in man focus attention
on skin manifestations because of their diagnostic speci-
ficity. However, data derived from population-based
studies; clinical case series; and reports relating to intake
of inorganic arsenic through drinking water, medications,
or occupational and environmental exposure, show that
chronic arsenic exposure adversely affects multiorgan
system of human body.
Skin manifestations
Pigmentation and keratosis are the specific skin diseases
characteristic of chronic arsenic toxicity. To ascertain the
prevalence of keratosis and pigmentation in relation to
arsenic exposure, the first population-based survey was
carried out on 7,683 participants (4,093 females and 3,590
males) in West Bengal with participants arsenic-exposure
data [7]. The arsenic content of current water source of the
participants ranged up to 3,400 mg/L; however, more than
80% of the participants consumed water with arsenic level
less than 50 mg/L. The age-adjusted prevalence of keratosis
and pigmentation was strongly related to water arsenic
levels, rising from 0 and 0.3 per 100, respectively, in the
lowest exposure level (<50 mg/L), to 8.3 and 11.5 per 100,
respectively, for females drinking water containing greater
than 800 mg/L arsenic, and increasing from 0.2 and 0.4 per
100, respectively, in the lowest exposure category, to 10.7
and 22.7 per 100, respectively, for males in the highest
exposure level (>800 mg/L). Calculation by dose per kilo-
gram body weight showed that men had roughly two to
three times the prevalence of both keratosis and pigmen-
tation compared with women apparently ingesting the
same dose of arsenic from drinking water. Participants who
were less than 80% of the standard body weight for their
age and sex had a 1.6-fold increase in the prevalence of
keratosis, suggesting that malnutrition may play some role
in increasing susceptibility. However, the survey examinedonly the participants’ primary current drinking-water
source. Results of a nested caseecontrol study using
detailed lifetime (at least 20 years) exposure assessment
showing low dose of arsenic exposure (<50 mg/L) among the
aforementioned study population were further available.
The exposure assessment incorporated arsenic concentra-
tion data from current and past water sources used in
households and work sites. The lowest peak arsenic level
ingested by a confirmed case was 115 mg/L. Strong dosee
response gradients with both peak and average arsenic
water concentrations were also observed [8]. In another
cross-sectional study, conducted in Bangladesh, 430 out of
1,481 participants aged 30 years or older and drinking
arsenic-contaminated water were found to have arsenical
skin lesions. Arsenic water concentrations ranged from
10 mg/L to 2,040 mg/L, and the crude overall prevalence
rate for skin lesions was 29%. This study also showed
a higher prevalence rate of arsenical skin lesions in males
than in females with clear doseeresponse relationship [9].
Systemic manifestations
Chronic arsenic toxicity produces various systemic mani-
festations over and above skin lesions. It needs to be noted
that although systemic manifestations occur mostly in
association with arsenical skin lesions, symptoms do occur
in significantly higher number of cases in arsenic-exposed
people even in the absence of arsenical skin disease
compared with arsenic-unexposed people [10].
Respiratory disease
Initial report of nonmalignant lung disease was available
from a study of 180 residents of Antofagasta, Chile,
exposed to drinking water containing arsenic (800 mg/L).
About 38% of the 144 participants with abnormal skin
pigmentation complained of chronic cough, compared with
3.1% of 36 participants with normal skin [11]. Symptoms of
chronic lung disease were present in 89 (57%) out of 156
cases of chronic arsenic toxicity caused by drinking arsenic-
contaminated water in West Bengal (Table 1) [12]. Lung
function tests carried out on 17 patients showed features of
restrictive lung disease in nine (53%) and combined
obstructive and restrictive lung disease in seven (41%)
cases.
To ascertain the relationship of chronic arsenic exposure
with occurrence of lung disease, an analysis of data of
cross-sectional epidemiological survey of nonsmokers
(6,864 participants) was carried out in West Bengal. The
study participants included those who had arsenic-associ-
ated skin lesions and who were also highly exposed at the
time of the survey (arsenic water concentration 50 mg/L).
Participants with normal skin and low arsenic water
concentration (<50 mg/L) were used as the reference
group. In participants with skin lesions, the age-adjusted
prevalence odds ratio (OR) estimates for cough, crepita-
tions, and shortness of breath for females were 7.8, 9.6,
and 23.2, respectively, and for males, 5, 6.9, and 3.7,
respectively [13]. In an epidemiological study carried out
on 218 nonsmokers (94 exposed to arsenic, 136e1,000 mg/L,
and 124 unexposed cases) in Bangladesh, the crude
Table 1 Symptoms and signs of 167 arsenicosis patients
during hospital admission in West Bengal, India
n %
Symptoms
Weakness 110 70.5
Headache 32 20.5
Burning of the eyes 69 44.2
Nausea 17 10.9
Pain in the abdomen 60 38.4
Epigastric 39 25.0
Paraumbilical 21 13.4
Diarrhea 51 32.6
Cough 89 57.0
With expectoration 53 33.9
Without expectoration 36 23.1
Hemoptysis 8 5.1
Dyspnea 37 23.7
Paresthesia 74 47.4
Signs
Pigmentation 156 100.0
Keratosis 96 61.5
Anemia 74 47.4
Hepatomegaly 120 76.9
Splenomegaly 49 31.4
Ascites 5 3.0
Pedal edema 18 11.5
Sign of lung disease 45 28.8
Sign of polyneuropathy 21 13.4
Adapted from Ref. [12].
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1.6 [95% confidence interval (CI): 0.8e3.1] and 10.3 (95% CI:
2.4e43.1) for males and females, respectively [14].
During 1998e2000, relationship between lung function
and exposure to arsenic in drinking water was ascertained
in West Bengal among a cohort of 287 participants selected
among study population who were exposed to low dose of
arsenic (up to 500 mg/L) [15]. The average forced expira-
tory volume in 1 second, adjusted for age, height, and
smoking, was reduced by 256.2 mL (95% CIZ 113.9e398.4,
p< 0.001), and the average adjusted forced vital capacity
reduced by 287.8 mL (95% CIZ 134.9e440.8, p< 0.001) in
men with skin lesions compared with those without skin
lesions. An increase of 100 mg/L arsenic in drinking water
was associated with a decrease in forced expiratory volume
in 1 second of 45 mL (95% CIZ 6.2e83.9, pZ 0.02) and
a decrease in forced vital capacity of 41.4 mL (95%
CIZ 0.7e83.5, pZ 0.05) in men. Women showed little
evidence of lung function alteration. Thus, over and above
respiratory symptoms, consumption of arsenic-contami-
nated water in man was found to be associated with
reduced pulmonary function.
In a hospital-based study carried out on 29 cases of
chronic arsenic toxicity with nonmalignant lung disease in
Kolkata, West Bengal [16], obstructive lung disease was
diagnosed in 17 (58.6%), interstitial lung disease in nine
(31.2%), and bronchiectasis in three (10%) cases. To ascer-
tain the incidence of bronchiectasis in the population, 108
participants with arsenic-caused skin lesions and 150participants without skin lesions were studied in an arsenic-
endemic population in West Bengal [17,18]. The median
highest level of arsenic in drinking water was 330 mg/L
[standard deviation (SD)Z881 mg/L] in participants with
skin lesions compared with 28 mg/L (SDZ147 mg/L) in
those without such lesions. Thirty-eight study participants
who reported at least 2 years of chronic cough underwent
high-resolution computed tomography. The mean bronchi-
ectasis severity score was 3.4 (SDZ3.6) in the 27
participants with skin lesions and 0.9 (SDZ1.6) in the 11
participants without these lesions (controls). In participants
who reported chronic cough, high-resolution computed
tomography evidence of bronchiectasis was found in 18
(67%) cases with skin lesion and in three (27%) controls.
Adjusted OR was found to be 10.1 (95% CIZ 2.7e37.1). This
study showed that drinking high-arsenic-contaminated
water was associated with increased incidence of bronchi-
ectasis in man. Many other investigators also reported
chronic respiratory disease in the form of chronic cough or
chronic bronchitis because of prolonged drinking of arsenic-
contaminated water [19e21].
Gastrointestinal disease
Dyspepsia was observed in 60 out of 156 (38.4%) cases of
chronic arsenic toxicity studied in West Bengal (Table 1)
[12]. However, in an epidemiological study carried out in
the affected population, there was no difference in the
incidence of pain in abdomen among people drinking
arsenic-contaminated water and the control population
(27.84% vs. 31.81%) [22]. Gastroenteritis was reported in
a study of 1,447 cases of chronic arsenicosis caused by
drinking arsenic-contaminated water with a concentration
greater than 50 mg/L in the Inner Mongolian Autonomous
Region of China [20]. Many investigators variously reported
symptoms, such as nausea, diarrhea, anorexia, and
abdominal pain in cases of chronic arsenic toxicity
[5,11,23e25].
Liver disease
Many workers have reported, earlier, cases of liver damage
after treatment of patients with arsenic as Fowler’s
solution [26e28]. All these patients developed features of
portal hypertension with signs of liver fibrosis. Typical
cutaneous signs of long-term arsenic exposure were also
observed in some of the patients. There have also been
case reports of liver cirrhosis after medication with inor-
ganic arsenic compounds [29,30].
Hepatomegaly was found in 62 out of 67 members of
families who drank arsenic-contaminated water (200e
2,000 mg/L) in West Bengal, whereas it was found in only
6 out of 96 people who drank safe water in the same
area. Thirteen of those arsenic-exposed patients who had
hepatomegaly were further investigated in a hospital. All
showed various degrees of portal zone expansion and
fibrosis on liver histology. Four out of five patients who had
splenomegaly showed evidence of increased intrasplenic
pressure (30-cm to 36-cm saline), suggesting portal hyper-
tension. Splenoportography done in those cases showed
evidence of intrahepatic portal vein obstruction. Although
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cases investigated, the bromsulphthalein retention test,
done in three patients, was found to be abnormal. The
arsenic level in liver tissue (estimated by neutron activation
analysis) was found to be elevated in 10 out of 13 cases (As
levelsdcases: 500e6,000 mg/L/kg; controls: 100 40 mg/L/
kg) [5]. In a subsequent report from the same hospital,
hepatomegaly was found in 190 out of 248 cases of chronic
arsenicosis investigated. Evidence of portal fibrosis on liver
histology was found in 63 out of 69 cases of hepatomegaly
who were biopsied. Liver function tests carried out in 93
such patients showed evidence of elevation of alanine
transaminase, aspartate transaminase, and alkine phos-
phatase, in 25.8%, 6.3%, and 29% of cases, respectively.
Serum globulin was found to be high (>3.5 g/dL) in 19
(20.7%) cases [31].
In an epidemiological study carried out in West Bengal,
the incidence of hepatomegaly was found to have a linear
relationship with increasing exposure of arsenic in drinking
water in both sexes (p< 0.001) [22]. Liver enlargement was
also reported after drinking of arsenic-contaminated water
by other workers [19e21,32]. All these studies show that
prolonged drinking of arsenic-contaminated water is asso-
ciated with hepatomegaly, the predominant lesion being
hepatic fibrosis.
Cardiovascular disease
Blackfoot disease (BFD), a form of peripheral vascular
disease, has been reported to be one of the important
complications of chronic arsenic toxicity in Taiwan. The
prevalence of BFD has been reported to be 8.9 per 1,000
among 40,421 inhabitants studied in Taiwan [33]. Compa-
rable peripheral vascular disorders with varying degrees of
severity, including Raynaud’s syndrome and acrocyanosis,
have also been reported among people drinking arsenic-
contaminated water by others [11,12,19,20,30,33]. The
incidence of peripheral vascular disease was found to be low
inWest Bengal. Out of 246 arsenicosis patients who attended
a referral hospital in Kolkata, three cases (1.2%) of peripheral
vascular disease were found [22]. However, out of 4,865
cases surveyed in a village population of West Bengal, one
case (0.02%) of gangrene was detected [32]. Similarly, low
incidence has been found in Chile and Bangladesh, whereas
there is no report from Mexico and Argentina [34].
An epidemiological study reported an increased preva-
lence of hypertension among residents in the endemic area
of BFD and a doseeresponse relationship between ingested
inorganic arsenic and prevalence of hypertension [35]. An
association of cumulative arsenic exposure in drinking water
was also found with increased risk of hypertension in a study
of 1,595 people in Bangladesh [36]. Increased prevalence of
hypertension was also reported in 6.2% patients affected
with arsenic-induced skin lesions (144) compared with none
without skin lesion in Antofagasta, Chile [11]. Increased
incidence of hypertension was found in a study of 108
arsenicosis cases compared with 100 arsenic-unexposed
participants in a rural population in West Bengal (Guha
Mazumder, unpublished data). Mortality rates from ischemic
heart disease with endemic arsenicosis (from 1973 through
1986) were correlated with the arsenic level in drinking
water among residents of 60 villages in Taiwan [37].Diseases of nervous system
There are many reports of occurrence of peripheral
neuropathy because of chronic exposure of arsenic through
drinking water [20,21,24,32,38,39]. Peripheral neuritis
characterized by paresthesia (tingling, numbness, limb
weakness, and others) was present in 74 (47.4%) out of 156
patients of chronic arsenicosis as a result of drinking arsenic-
contaminated water (500e14,200 mg/L) in West Bengal,
India (Table 1). Objective evaluation of neuronal involve-
ment, done in 29 patients, showed abnormal electromyog-
raphy (EMG) in 10 (30.8%) and altered nerve conduction
velocity and EMG in 11 (38%) cases [12,40]. In another
electrophysiological study carried out on 88 patients of
arsenicosis in West Bengal, sensory neuropathy was found in
24 (27.3%), motor neuropathy in 13 (14.7%), and abnormal
EMG in 5 (5.7%) cases [41]. Abnormal EMG findings, sugges-
tive mostly of sensory neuropathy, was reported in 10 out of
32 participants exposed to drinking arsenic-contaminated
well water (range, 60e1,400 mg/L) in Canada [42].
There are several reports of increased incidence of
cerebrovascular disease in patients suffering from chronic
arsenicosis [20,38,43]. However, no study data are avail-
able from West Bengal regarding the occurrence of cere-
brovascular disease.
Peripheral neuritis, sleep disturbances, weakness, and
cognitive and memory impairment have been reported in
residents of Byan College Station, Texas, exposed to arsenic
from air and water from arsenic trioxide used to produce
defoliants from an Atochem plant (TX,USA) [39]. Headache
has been reported to occur in people drinking arsenic-
contaminated water in Mexico [24] and in West Bengal
(Table 1) [12]. Irritability, lack of concentration, depres-
sion, sleep disorders, headache, and vertigo were reported
in arsenicosis people showing features of neuropathy in
West Bengal [41].
Hematological effects
Hematological abnormalities have been reported in acute
and chronic arsenic poisoning [44]. A characteristic pattern
of anemia, leucopenia, and thrombocytopenia was found
in 55 participants exposed to arsenic in drinking water in
Niigata Prefecture in Japan for approximately 5 years,
half of the patients having arsenical skin lesions [44]. In
one study in West Bengal, anemia was reported in all the
13 people exposed to arsenic-contaminated groundwater
(200e2,000 mg/L) [5]. Further study in West Bengal on
156 people exposed to arsenic-contaminated water
(50e14,200 mg/L) showed incidence of anemia in 47.4% of
cases (Table 1) [12]. However, no association of anemia was
found in people drinking well water (mean, 220 mg/L) in
Alaska [45] and in two towns of Utah (arsenic exposure,
180 mg/L and 270 mg/L) [46].
Diabetes
A doseeresponse relationship between cumulative arsenic
exposure and prevalence of diabetes mellitus was observed
in Taiwan after a study on 891 persons living in arsenic-
endemic areas [47]. From Bangladesh, significantly
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drinking arsenic-contaminated water was also reported
among individuals with keratosis compared with those who
did not have such lesions [48]. However, no study on the
incidence of diabetes mellitus in arsenicosis has been
carried out in West Bengal.Figure 2. Nonpitting edema of legs with keratosis in
a patient of arsenicosis.Pregnancy outcome
Limited information on pregnancy outcome and infant
mortality in relation to arsenic levels in drinking water is
available in literature as few studies included participants
assessment of arsenic concentrations in all water sources
used during each pregnancy. A retrospective study of
pregnancy outcomes and infant mortality was conducted in
West Bengal, India, among 202 married women selected
from a source population of 7,683 between the years 2001
and 2003. Reproductive histories were ascertained by
structured interviews. Arsenic exposure during each preg-
nancy was assessed based on all water sources used,
involving measurements from 409 wells. Odds ratios for
spontaneous abortions, stillbirth, and neonatal and infant
mortality were estimated with logistic regressions based on
the method of generalized estimating equations. High
concentration of arsenic, greater than or equal to 200 mg/L,
during pregnancy, was associated with a sixfold increased
risk of stillbirth after adjusting for potential confounders
(OR Z 6.25, 95% CIZ 1.59e24.6, pZ 0.009). Arsenic-
related skin lesions were found in 12 women who had
a substantially increased risk of stillbirth (ORZ 13.1, 95%
CIZ 3.17e54.0, pZ 0.002). The OR for neonatal death was
2.03 (95% CIZ 0.57e7.24). No association was found
between arsenic exposure and spontaneous abortion
(ORZ 0.90, 95% CIZ 0.36e2.26) or overall infant mortality
(ORZ 1.18, 95% CIZ 0.38e3.64). This study adds to the
limited evidence that exposure to high concentrations of
arsenic during pregnancy increases the risk of stillbirth.
However, there was no indication of increased rates of
spontaneous abortion and overall infant mortality [49].
In an ecological study carried out in Chile, stillbirth (rate
ratioZ 1.7; 95% CIZ 1.5e1.9) and neonatal and post-
neonatal infant mortality rates were found to be increased
in the high-arsenic-exposure city of Antofagasta as
compared with the low-exposure-city Valparaiso [50].
A study conducted in Bangladesh showed an increased risk
of stillbirth in women with current arsenic levels greater
than or equal to 100 mg/L, although the risk estimates were
smaller (ORZ 2.5; 95% CIZ 1.5e5.9). The authors further
reported increased effects on spontaneous abortions
(ORZ 2.5, 95% CIZ 1.5e4.4) [51]. However, no informa-
tion was available on arsenic exposure during pregnancy,
and high exposure levels of 200 mg/L and more were not
considered separately in this study. One earlier cross-
sectional study from Bangladesh compared the rates of
spontaneous abortions, stillbirths, and preterm deliveries
among 96 women in one village who were exposed to
greater than or equal to 100 mg/L arsenic with the rates in
96 women in another village who were exposed to less than
20 mg/L arsenic and showed two to three times higher rates
among exposed women [52]. Both the Bangladesh studies
reported a relationship with the overall duration ofwomen’s exposure without taking into account exposure
during the actual time period of pregnancy. In a recent
publication from Bangladesh, pregnancy outcome and
infant death were ascertained by health surveillance
program on 29,134 pregnancies with a history of drinking
arsenic-contaminated water with arsenic level greater than
50 mg/L. Significant increased risk of fetal loss (relative
riskZ 1.14, 95% CIZ 1.04e1.25) and infant death (relative
riskZ 1.17, 95% CIZ 1.04e1.32) was observed in this
study. There was a significant dose response of arsenic
exposure to risk of infant death (pZ 0.02) [53].
Other effects
High incidence of weakness and fatigue have been reported
in chronically arsenic-exposed people after drinking arsenic-
contaminated water in West Bengal and in many other
countries [5,12,22,23,32,39,54]. Conjunctival congestion
and nonpitting edema of the legs (Fig. 2) and hands have also
been reported in patients of chronic arsenic toxicity in West
Bengal and Bangladesh [12,21,25,55].
Arsenicosis and cancer
The evidence of carcinogenicity in humans from exposure
to arsenic is based on epidemiological studies of cancer in
relation to arsenic in drinking water. The working group of
International Agency for Research on Cancer [3] evaluated
data from ecological, cohort, and caseecontrol studies
from many countries and observed that arsenic was
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cancers as result of chronic exposure to arsenic. In West
Bengal, 212 (4.35%) cases of skin cancer and 38 (0.78%)
cases of internal cancers were detected among 4,865 cases
of arsenicosis studied in arsenic-affected villages [56].
Genotoxicity
Several studies have investigated the genotoxic effects of
arsenic after long-term exposure in drinking water.
Increased incidence of chromosomal aberration and
frequency of micronuclei in buccal and urothelial cells was
observed by many workers after drinking of arsenic-
contaminated water [3,57,58]. In a study in West Bengal,
the frequencies of micronuclei in oral mucosal cells, uro-
thelial cells, and peripheral lymphocytes were found to be
significantly high in 163 participants exposed to high level
of arsenic in drinking water (214.72 9.02 mg/L) compared
with 154 unexposed control participants with little arsenic
in drinking water (9.2 0.31 mg/L). The analyzed data
revealed that micronuclei frequencies in the exposed group
were significantly elevated to 5.33-fold over unexposed
levels for lymphocytes, 4.63-fold for oral mucosal cells, and
4.71-fold for urothelial cells (increases in micronuclei
frequencies significant at p< 0.01). The results indicate
that chronic ingestion of arsenic in drinking water in
exposed participants is linked to the enhanced incidence of
micronuclei in all the cell types, a slightly higher level of
micronuclei being observed in lymphocytes compared with
oral mucosal and urothelial cells [59]. Over and above
micronuclei study, further cytogenetic studies included the
study of chromosomal aberration on 422 (244 symptomatic
and 178 asymptomatic) participants. Higher level of cyto-
genetic damage was found in symptomatic participants
compared with asymptomatic participants, and asymp-
tomatic participants had significantly higher genotoxicity
than unexposed participants [60].
DNA damage
Various probable mechanisms have been incriminated to
cause DNA damage because of chronic arsenic toxicity.
Arsenic appears to have little ability, if any, to induce point
mutation [44,61]. Altered DNA repair, oxidative stress, cell
transformation, altered cell proliferation, altered cell
signaling, altered steroid receptor binding, and altered
gene expression and amplification are many of the mech-
anisms postulated to be involved in causing DNA damage
because of chronic arsenic exposure [3]. A study in Taiwan
showed that p53 gene mutation rate in arsenic-related skin
cancers from the BFD-endemic area of Taiwan was high,
and that the mutation types were different from those in
UV-induced skin cancers [62].
Altered DNA repair
To ascertain whether keratosis, a premalignant condition
associated with arsenicosis, is involved in the alteration in
DNA repair capacity, 30 individuals with keratosis exposed
to chronic arsenic-contaminated water and 30 unexposed
controls were studied in West Bengal by comet,chromosomal aberration (CA), and challenge assays. DNA
damage and CA was significantly higher in the arsenic-
exposed participants compared with those in unexposed
participants (p< 0.001). Within the exposed group, there
was no significant difference of DNA damage (p> 0.05), but
CA was significantly higher in the exposed group with
keratosis than in that without exposure (p< 0.01). Chal-
lenge assay showed that, on induction of DNA damage, the
repair capacity in the exposed group with keratosis was
significantly less (<0.001) than that of participants without
skin lesion, although the basal level of DNA damage was
similar in both. The results of the study suggested that
deficiency in DNA repair capacity may be involved in
arsenic-induced carcinogenesis [63].Altered DNA methylation
It has been hypothesized that alteration of DNA methyla-
tion by arsenic may play a role in the development of
cancer. This mechanism has been proposed because the
S-adenosyl methionine (SAM)/methyltransferase pathway
for biotransformation of arsenic overlaps with the DNA
methylation pathway, in which donation of methyl groups
from SAM to cytosine produces 5-methylcytosine in DNA.
DNA methylation is now known to be one of the main
epigenetic mechanisms, which perpetuates the repression of
genes in vertebrates and is intimately associated with
development. Hypermethylation and consequent silencing
of tumor suppressor and repair genes have been implicated
as an early step in many cancers, such as those of lung,
colorectum, breast, and others. Hypomethylation, on the
other hand, provides growth advantage. Earlier experi-
mental studies indicated that the carcinogenicity of arsenic
may be mediated by alteration in the methylation status of
DNA either by hypermethylation or hypomethylation [64,65].
To ascertain whether perturbation of methylation plays
a role in carcinogenesis in humans, the degree of methyl-
ation of p53 and p16 genes in DNA obtained from blood
samples of people chronically exposed to arsenic and skin
cancer patients was studied in West Bengal. Methylation-
specific restriction endonuclease digestion followed by
polymerase chain reaction (PCR) of gene p53 and bisulfite
treatment followed by methylation-sensitive PCR of gene
p16 have been carried out to analyze the methylation
status of the samples studied. Significant DNA hyper-
methylation of the promoter region of p53 gene was
observed in the DNA of arsenic-exposed people compared
with that of the control participants. This hypermethylation
showed a doseeresponse relationship. Furthermore,
hypermethylation of p53 gene isolated from peripheral
blood was also observed in arsenic-induced skin cancer
patients compared with that in individuals having skin
cancer unrelated to arsenic, though not at a significant
level. However, a small subgroup of cases showed hypo-
methylation with high arsenic exposure. Significant hyper-
methylation of gene p16 was also observed in cases exposed
to high level of arsenic [65]. Further DNA was isolated from
arsenic- and non-arsenic-induced skin cancer tissues, and
p53 promoter methylation was studied. The degree of
methylation in p53 promoter region of DNA of arsenic-
induced cancer biopsy tissues showed significantly higher
Chronic arsenic toxicity 367hypermethylation compared with the biopsy tissues
obtained from non-arsenic-induced skin cancer (p< 0.05)
[66].
The changes in methylation status of whole genome
becauseofarsenic exposurehavebeen studied inWestBengal
bymonitoring the variation ofmethyl acceptance capacity of
DNA extracted from peripheral blood of persons exposed to
various doses of arsenic using the SssI methylase assay. To
monitor the level of whole-genome methylation in persons
exposed to different levels of arsenic through drinking water,
DNA was extracted from peripheral blood mononuclear cells
of 64 persons. Uptake of methyl group from 3H-labeled
S-adenosyl methionine after incubation of DNA with SssI
methylase was measured. Results showed statistically
significant (pZ 0.0004) decrease in uptake of 3H methyl
group in the persons exposed to 250e500 mg/L arsenic, indi-
cating genomic hypermethylation. This significance is lost in
Group D that was exposed to greater than 500 mg/L of arsenic
in drinking water [67]. To explain the results, it is noted that
inorganic arsenic induces cytosine methyltransferase in
tissue culture system [68], and array analysis of tissue from
mice exposed to different doses of arsenic also showedup the
regulation of DNA methyltransferase 3a gene [69]. This can
cause the initial hypermethylation of DNA after arsenic
exposure. However, as arsenic load increases, its detoxifica-
tion through enzymatic methylation causes depletion of the
methyl donor SAM that has a vital role in the detoxification
process, leading to inefficient arsenic excretion, and DNA
hypomethylation. DNA methyltransferase uses the same
methyl donor SAM, andmaintenancemethylation is disrupted
when the level of SAM in the bodydrops. In the last groupwith
arsenic dose greater than 500 mg/L, there is probably too
much methionine requirement for excretion of the large
amount of arsenic ingested, and the extent of hyper-
methylation is no longer statistically significant because of
the reduced SAM level. This probably signifies the beginning
of the process of hypomethylation. It might be mentioned
that, in an earlier work too, a small number of samples of the
group having much higher dose of arsenic exposure showed
hypomethylation, the level of significance increasing from
0.02 to 0.001 as the arsenic dose increased [70].
Genetic polymorphism
Arsenic-induced keratosis is considered as a precancerous
state of in situ carcinoma of skin. Several reports have
suggested the role of p53 polymorphisms as a potential
marker for the risk assessment of different types of
cancers. This prompted to study the association of three
p53 polymorphisms with arsenic-induced keratosis in
a population exposed to arsenic through drinking water.
A total of 366 unrelated participants (177 participants with
arsenic-induced keratosis and 189 participants with no
arsenical skin lesions) were recruited from North 24 Par-
ganas, Nadia, and Murshidabad districts of West Bengal for
study of genotype distribution of three p53 polymorphisms
[16-bp duplication at intron 3, codon 72 Arg/Pro, and G>A
at intron 6 (nt 13,494)] by PCR-restriction fragment length
polymorphism. The arginine homozygous genotype at codon
72 and homozygous genotype of no duplication poly-
morphism at intron 3 were overrepresented in theparticipants with keratosis compared with participants with
no skin lesion (ORZ 2.086, 95% CIZ 1.318e3.299; and
ORZ 2.086, 95% CIZ 1.257e3.457, respectively). This
study indicated that participants carrying the arginine
homozygous genotype of codon 72 and/or no duplication
homozygous genotype at intron 3 are at risk for the
development of arsenic-induced keratosis [71].
Studies from 115 study participants from Taiwan showed
that genetic polymorphisms of GSTM1 and GSTT1 were
significantly associated with arsenic methylation. Partici-
pants having the null genotype of GSTM1 had an increased
percentage of inorganic arsenic in urine, whereas those
with null genotype of GSTT1 had elevated percentage of
DMA in urine [72].
A further study on 170 participants in Argentina showed
that women with null genotype of GSTM1 excreted a signif-
icantly higher proportion of arsenic as monomethylarsonic
acid than women with active genotype [73]. However,
incidence in GSTM1 null gene frequencies studied in 244 skin
symptomatic participants and 178 asymptomatic partici-
pants exposed to arsenic in West Bengal, significantly higher
GSTM1 null gene frequencies were found in the asymptom-
atic group. No difference in allelic variants in GSTT1 and
GSTP1was observed between these two groups [60]. Studies
from 600 cases and controls (each) in Bangladesh also did not
find any significant interaction for GSTM1 for primary
methylation ratio. The investigators observed significant
interaction on the multiplicative scale between the GSTT1
wild type and secondary methylation ratio [74].
To find out any probable association between arsenicosis
and the exonic single-nucleotide polymorphisms of genes
involved in the regulation of arsenic metabolism, purine
nucleoside phosphorylase (PNP), arsenic(þ3) methyl-
transferase, and glutathione S-transferase omega 1 and
omega 2 were studied in arsenic-exposed population in
West Bengal. Among the four candidate genes, distribution
of three exonic polymorphisms, His 20His, Gly 51Ser, and
Pro 57Pro of PNP was found to be associated with arsen-
icosis. Genotypes with minor alleles were significantly
overrepresented in the case group: ORZ 1.69 (95% CIZ
1.08e2.66) for His 20His; ORZ 1.66 (95% CIZ 1.04e2.64)
for Gly 51Ser; and ORZ 1.67 (95% CIZ 1.05e2.66) for Pro
57Pro.The results indicate that three PNP variants render
participants susceptible toward developing arsenic-induced
skin lesions [75].
Discussion and conclusion
Chronic arsenic toxicity (arsenicosis) as a result of drinking
arsenic-contaminated groundwater is a major environ-
mental health hazard throughout the world, including
India. A lot of new information is emerging from extensive
research on health effects of chronic arsenic toxicity in
humans during the last two decades. Pigmentation and
keratosis are the specific skin lesions characteristic of
chronic arsenic toxicity. Of the various systemic manifes-
tations, chronic lung disease, peripheral neuropathy, and
chronic liver disease appeared to be the major causes of
morbidity reported by most of the investigators from
different parts of the world [76]. A systematic review of
the epidemiological evidence on arsenic exposure and
368 D.N. Guha Mazumder, U.B. Dasguptacardiovascular disease showed that methodological limita-
tions restricted the interpretation of the moderate to
strong association between high arsenic exposure and
cardiovascular outcome in Taiwan. In other populations and
in occupational setting, the evidence was inconclusive [77].
There is consensus in all the studies on pregnancy outcome
with the finding that stillbirth occurs in significantly higher
number of cases in pregnant women with chronic arsenic
exposure. There is sufficient epidemiological evidence to
incriminate arsenic as an important cause of cancers of
skin, lungs, and urinary bladder [3].
Arsenic causing genotoxicity as a result of drinking
arsenic-contaminated water has been extensively studied in
West Bengal. Chromosomal aberration and increased
frequency of micronuclei in different cell types have been
found to be significant. Further studies are needed to
ascertain whether these could be used as biomarker of
chronic arsenic toxicity. Various probable mechanisms have
been incriminated to cause DNA damage because of chronic
arsenic toxicity and have been correlated with disease
manifestations. However, further studies are needed to
establish specific genotoxic effects of arsenic in causing
cancer. There appears to be no consensus with the various
findings of genetic polymorphism and diseasemanifestation.
The key approach for addressing the arsenic problem is
to provide scientifically correct information to the people
at risk and develop comprehensive water-quality surveil-
lance system. The most important step is to arrange for
identification of arsenic-contaminated tube wells and make
the people aware of not drinking arsenic-contaminated
water. Management of health effect because of arsenic
toxicity requires an integrated approach of collaboration of
health personnel of Ministry of Health and engineering
personnel of Public Health Engineering Department of the
government. For its mitigation in a developing country,
such as India, assistances may also be required from
nongovernmental organizations and international agencies,
for example, World Health Organization, United Nations
Children’s Fund, and World Bank. Research on epidemi-
ology, including determination of disease burden in the
population, confounding factors for variability in disease
manifestation, standardization of proper disease manage-
ment protocol, and arsenic in food chain and human health
are some of the issues that require further attention.References
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